B
Bull
Bull · 25%EWTX
$16.79
Scenario price
$38.200
+1.219 (+3.19%)At close
Loading chart…
- High
- 38.530
- Open
- 37.620
- VWAP
- 37.99
- Volume
- 1.84M
- Mkt Cap
- 1.63B
- Low
- 37.240
- Amount
- 69.81M
- EV/EBITDA, TTM
- 0.00
Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on cardiovascular diseases. The Company is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy, heart failure and other serious cardiovascular and cardio metabolic conditions. The Company's pipeline comprises the EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF and EDG-003. EDG-7500 is a novel, oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction which is being studied in a multipart Phase 2 trial for the potential treatment of obstructive and nonobstructive HCM. The Company is also developing EDG-15400, which is in a Phase 1 trial of healthy adults with the future disease target of heart failure with preserved ejection fraction (HFpEF).
AI analysis of Edgewise Therapeutics Inc (EWTX)
HoldEdgewise Therapeutics is currently a hold. The stock is priced at $39.06, which is below the average analyst price target of $50. However, the RSI is at 30.205, indicating it is oversold, and the stock has a significant year-to-date change of +64.46%. The main risk is the negative earnings trend, with a reported EPS of -0.53 in the last quarter, which may affect investor confidence.
Valuation Metrics
The current forward P/E ratio for Edgewise Therapeutics Inc (EWTX) is 0.00, compared to its 5-year average forward P/E of -9.08.
Alphio AI Price Scenarios for EWTX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding EWTX
Events Timeline
News
2.010-08PRnewswireEdgewise Initiates Phase 2 HFpEF Clinical Trial for EDG-15400
8.509-22PRnewswireEdgewise Therapeutics Advances EDG-7500 for Heart Disease Treatment
9.009-22NewsfilterEdgewise Therapeutics Advances EDG-7500 for Heart Disease Treatment
8.508-24PRnewswireEdgewise Presents Positive Data from HCM Trial of EDG-7500
- 9.508-06seekingalpha
Edgewise Therapeutics Reports Q2 Financial Results and Updates on EDG-7500 Trial
EWTX FAQ — answered by Alphio AI
Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on cardiovascular diseases. The Company is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy, heart failure and other serious cardiovascular and cardio metabolic conditions. The Company's pipeline comprises the EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF and EDG-003. EDG-7500 is a novel, oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction which is being studied in a multipart Phase 2 trial for the potential treatment of obstructive and nonobstructive HCM. The Company is also developing EDG-15400, which is in a Phase 1 trial of healthy adults with the future disease target of heart failure with preserved ejection fraction (HFpEF). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Edgewise Therapeutics is currently a hold. The stock is priced at $39.06, which is below the average analyst price target of $50. However, the RSI is at 30.205, indicating it is oversold, and the stock has a significant year-to-date change of +64.46%. The main risk is the negative earnings trend, with a reported EPS of -0.53 in the last quarter, which may affect investor confidence.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.